|
CHONGQING ENSKY PHARMACEUTICAL CO., LTD.
|
Located in Chongqing, China, Chongqing inskay Chemical Co., Ltd. is a private joint-stock enterprise specializing in the development, production and operation of pharmaceutical intermediates and fine chemical products. At present, the company mainly produces more than 20 kinds of products such as indoles and quinolines, which are exported to Europe, America and other countries and regions. The company has a strong technical force, with a group of professional and technical personnel who have rich experience in pharmaceutical production and sales industry, and are committed to the development and research of pharmaceutical intermediates and fine chemical products. The company also cooperates closely with scientific research institutions with strong R & D capabilities at home and abroad to actively research and promote new products, new technologies and advanced production processes. While striving to expand the international market, the company is also committed to cooperating with excellent domestic pharmaceutical enterprises to provide them with high-quality products and efficient services. In order to meet the needs of sustainable development, the company has established a new production base in Chongqing chuanran general factory located in Chongqing Chemical Industry Park. The completion and operation of the base will provide more stable and reliable production and service guarantee for our customers. We are looking forward to working with you to create a better future! |
Send Inquiry
|
|
Shandong Sihuan Pharmaceutical Co.,Ltd.
|
Product Name: (R)-3-Piperidinamine dihydrochloride
Synonyms: R-3-AMnio piperidine dihydrochloride;(R)-PIPERIDIN-3-YLAMINE DIHYDROCHLORIDE;(R)-PIPERIDINE-3-AMINE DIHYDROCHLORIDE;(R)-(-)-3-AMINOPIPERIDINE DIHYDROCHLORIDE;(R)-3-AMINOPIPERIDINE DIHYDROCHLORIDE;(R)-3-PIPERIDINAMINE DIHYDROCHLORIDE;R-3-AMINOPIPERIDINE DIHCL;Linagliptin interMediate D
CAS: 334618-23-4
MF: C5H14Cl2N2
MW: 173.08406
EINECS: 608-870-9 |
Send Inquiry
|
Pharma Sources Insight January 2025
